Search

Displaying results 3311 - 3320 of 8196 in total
  1. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. Bruton's tyrosine kinase plays a role in B cell r...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  2. Drug

    Huperzine A

    go.drugbank.com/drugs/DB04864
    ApprovedInvestigationalWithdrawn

    Huperzine A, is a naturally occurring sesquiterpene alkaloid found in the extracts of the firmoss Huperzia serrata. The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in ...

  3. Drug

    Flurazepam

    go.drugbank.com/drugs/DB00690
    ApprovedIllicit

    A benzodiazepine derivative used mainly as a hypnotic.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  4. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion

  5. Drug

    Meningococcal polysaccharide vaccine group Y

    go.drugbank.com/drugs/DB13888
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.

  6. Drug

    Cidofovir

    go.drugbank.com/drugs/DB00369
    ApprovedInvestigational

    Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS.

  7. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid … [F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking

  8. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.

  9. Drug

    Inecalcitol

    go.drugbank.com/drugs/DB04796
    Investigational

    Categories: Vitamin D and Analogues
  10. Drug

    Piflufolastat F 18

    go.drugbank.com/drugs/DB14805
    ApprovedInvestigational

    Prostate cancer is the most common non-cutaneous malignancy affecting men in North America[A235344] - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent … [L34319] The images generated by positron emission tomography (PET) are less detailed than those obtained via MRI or CT, but are more sensitive and can reveal cancerous tissue in any area of the body provided